These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 30139716

  • 1. De Novo, Progressed, and Neglected Metastatic Castration-Sensitive Prostate Cancer: Is One Therapy Fit for All?
    Iacovelli R, Ciccarese C, Mosillo C, Tortora G.
    Clin Genitourin Cancer; 2018 Dec; 16(6):482-484. PubMed ID: 30139716
    [Abstract] [Full Text] [Related]

  • 2. [Modern treatment of metastatic hormone-sensitive prostate cancer].
    Küronya Z, Bíró K, Géczi L, Maráz A.
    Orv Hetil; 2018 Oct; 159(41):1664-1671. PubMed ID: 30295043
    [Abstract] [Full Text] [Related]

  • 3. Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea.
    Cho IC, Joung JY, Seo HK, Chung J, Park WS, Lee KH.
    J Cancer Res Ther; 2014 Oct; 10(2):251-7. PubMed ID: 25022374
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Ueda Y, Matsubara N, Takizawa I, Nishiyama T, Tabata K, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H.
    Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival.
    Thomas C, Brandt MP, Baldauf S, Tsaur I, Frees S, Borgmann H, Jäger W, Bartsch G, Schneider M, Dotzauer R, Neisius A, Haferkamp A.
    Int Urol Nephrol; 2018 Oct; 50(10):1821-1827. PubMed ID: 30120678
    [Abstract] [Full Text] [Related]

  • 9. Impact of Prior Local Treatment on the Outcomes of Metastatic Hormone-Sensitive Prostate Cancer: Secondary Analysis of a Randomized Controlled Trial.
    Abdel-Rahman O, Cheung WY.
    Clin Genitourin Cancer; 2018 Dec; 16(6):466-472. PubMed ID: 30098982
    [Abstract] [Full Text] [Related]

  • 10. Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.
    Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B.
    Eur Urol; 2016 Jun; 69(6):992-5. PubMed ID: 26724258
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PFA, Small EJ, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TW.
    Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
    [Abstract] [Full Text] [Related]

  • 13. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
    Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R, ELM-PC 4 investigators.
    Lancet Oncol; 2015 Mar; 16(3):338-48. PubMed ID: 25701170
    [Abstract] [Full Text] [Related]

  • 14. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
    Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES.
    Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
    [Abstract] [Full Text] [Related]

  • 15. Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases.
    Kapoor A, Wong NC, Wang Y, Mukherjee S, Hotte S, Dayes I, Lukka H.
    Asian J Androl; 2020 Nov; 22(4):437-438. PubMed ID: 31535625
    [No Abstract] [Full Text] [Related]

  • 16. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
    van Soest RJ, de Morrée ES, Shen L, Tannock IF, Eisenberger MA, de Wit R.
    Eur Urol; 2014 Aug; 66(2):330-6. PubMed ID: 23957945
    [Abstract] [Full Text] [Related]

  • 17. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
    Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE, COU-AA-302 Investigators.
    Lancet Oncol; 2015 Feb; 16(2):152-60. PubMed ID: 25601341
    [Abstract] [Full Text] [Related]

  • 18. Interim Results From ERADICATE: An Open-Label Phase 2 Study of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Castration-Resistant Prostate Cancer Subjects With Symptomatic Bone Metastases.
    Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 5):3-7. PubMed ID: 27167841
    [No Abstract] [Full Text] [Related]

  • 19. Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions.
    Iacovelli R, Ciccarese C, Schinzari G, Maiorano BA, Rossi E, Pierconti F, Bassi PF, Bria E, Tortora G.
    Crit Rev Oncol Hematol; 2019 Jul; 139():83-86. PubMed ID: 31112886
    [Abstract] [Full Text] [Related]

  • 20. Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer.
    Szarvas T, Sevcenco S, Módos O, Keresztes D, Nyirády P, Kubik A, Romics M, Kovalszky I, Reis H, Hadaschik B, Shariat SF, Kramer G.
    Urol Oncol; 2018 Jun; 36(6):312.e9-312.e15. PubMed ID: 29628317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.